APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dupilumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dupilumab Injection Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchDupilumab Injection Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Dupilumab Injection Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Dupilumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dupilumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Dupilumab Injection Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Dupilumab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dupilumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dupilumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dupilumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dupilumab Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dupilumab Injection market include Regeneron and Sanofi among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dupilumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dupilumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dupilumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dupilumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Dupilumab Injection Segment by Company

Regeneron

Sanofi

Dupilumab Injection Segment by Type

200mg (1.14mL)/Vial

300mg (2.0 mL)/Vial

Dupilumab Injection Segment by Application

Asthma

Atopic Dermatitis

Chronic Sinusitis with Nasal Polyps

Other

Dupilumab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dupilumab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dupilumab Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dupilumab Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Dupilumab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dupilumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dupilumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dupilumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dupilumab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dupilumab Injection industry.

Chapter 3: Detailed analysis of Dupilumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dupilumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dupilumab Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dupilumab Injection Industry Trends Table 2. Dupilumab Injection Industry Drivers Table 3. Dupilumab Injection Industry Opportunities and Challenges Table 4. Dupilumab Injection Industry Restraints Table 5. Global Dupilumab Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dupilumab Injection Revenue Share by Company (2021-2026) Table 7. Global Dupilumab Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Dupilumab Injection Sales Volume Share by Company (2021-2026) Table 9. Global Dupilumab Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dupilumab Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dupilumab Injection Key Company Manufacturing Base & Headquarters Table 12. Global Dupilumab Injection Company, Product Type & Application Table 13. Global Dupilumab Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dupilumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 200mg (1.14mL)/Vial Table 18. Significant Companies of 300mg (2.0 mL)/Vial Table 19. Global Dupilumab Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Dupilumab Injection Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Dupilumab Injection Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Dupilumab Injection Sales Volume Share by Type (2021-2026) Table 23. Global Dupilumab Injection Sales Volume Share by Type (2027-2032) Table 24. Global Dupilumab Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Dupilumab Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Dupilumab Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Dupilumab Injection Sales Value Share by Type (2021-2026) Table 28. Global Dupilumab Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Asthma Table 30. Significant Companies of Atopic Dermatitis Table 31. Significant Companies of Chronic Sinusitis with Nasal Polyps Table 32. Significant Companies of Other Table 33. Global Dupilumab Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Dupilumab Injection Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Dupilumab Injection Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Dupilumab Injection Sales Volume Share by Application (2021-2026) Table 37. Global Dupilumab Injection Sales Volume Share by Application (2027-2032) Table 38. Global Dupilumab Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Dupilumab Injection Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Dupilumab Injection Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Dupilumab Injection Sales Value Share by Application (2021-2026) Table 42. Global Dupilumab Injection Sales Value Share by Application (2027-2032) Table 43. Global Dupilumab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Dupilumab Injection Sales by Region (2021-2026) & (K Units) Table 45. Global Dupilumab Injection Sales Market Share by Region (2021-2026) Table 46. Global Dupilumab Injection Sales by Region (2027-2032) & (K Units) Table 47. Global Dupilumab Injection Sales Market Share by Region (2027-2032) Table 48. Global Dupilumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Dupilumab Injection Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Dupilumab Injection Sales Value Share by Region (2021-2026) Table 51. Global Dupilumab Injection Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Dupilumab Injection Sales Value Share by Region (2027-2032) Table 53. Global Dupilumab Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Dupilumab Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Dupilumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Dupilumab Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Dupilumab Injection Sales by Country (2021-2026) & (K Units) Table 58. Global Dupilumab Injection Sales Market Share by Country (2021-2026) Table 59. Global Dupilumab Injection Sales by Country (2027-2032) & (K Units) Table 60. Global Dupilumab Injection Sales Market Share by Country (2027-2032) Table 61. Global Dupilumab Injection Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Dupilumab Injection Sales Value Market Share by Country (2021-2026) Table 63. Global Dupilumab Injection Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Dupilumab Injection Sales Value Market Share by Country (2027-2032) Table 65. Regeneron Company Information Table 66. Regeneron Business Overview Table 67. Regeneron Dupilumab Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Regeneron Dupilumab Injection Product Portfolio Table 69. Regeneron Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Dupilumab Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sanofi Dupilumab Injection Product Portfolio Table 74. Sanofi Recent Development Table 75. Key Raw Materials Table 76. Raw Materials Key Suppliers Table 77. Dupilumab Injection Distributors List Table 78. Dupilumab Injection Customers List Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Dupilumab Injection Product Image Figure 2. Global Dupilumab Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dupilumab Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dupilumab Injection Sales (2021-2032) & (K Units) Figure 5. Global Dupilumab Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dupilumab Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 200mg (1.14mL)/Vial Image Figure 10. 300mg (2.0 mL)/Vial Image Figure 11. Global Dupilumab Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Dupilumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Dupilumab Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Dupilumab Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Dupilumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Dupilumab Injection Sales Value Share by Type (2021-2032) Figure 17. Asthma Image Figure 18. Atopic Dermatitis Image Figure 19. Chronic Sinusitis with Nasal Polyps Image Figure 20. Other Image Figure 21. Global Dupilumab Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Dupilumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Dupilumab Injection Sales Volume Share by Application (2021-2032) Figure 24. Global Dupilumab Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Dupilumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Dupilumab Injection Sales Value Share by Application (2021-2032) Figure 27. Global Dupilumab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Dupilumab Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Dupilumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Dupilumab Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Dupilumab Injection Sales Value (2021-2032) & (US$ Million) Figure 32. North America Dupilumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Dupilumab Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Dupilumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Dupilumab Injection Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Dupilumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Dupilumab Injection Sales Value (2021-2032) & (US$ Million) Figure 38. South America Dupilumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Dupilumab Injection Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Dupilumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Dupilumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Dupilumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Dupilumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Dupilumab Injection Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Dupilumab Injection Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 200mg (1.14mL)/Vial
  • 300mg (2.0 mL)/Vial
Applications
  • Asthma
  • Atopic Dermatitis
  • Chronic Sinusitis with Nasal Polyps
  • Other
Companies covered
  • Regeneron
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dupilumab Injection Sales Value (2021-2032)
  4. 1.2.2 Global Dupilumab Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Dupilumab Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dupilumab Injection Market Dynamics
  1. 2.1 Dupilumab Injection Industry Trends
  2. 2.2 Dupilumab Injection Industry Drivers
  3. 2.3 Dupilumab Injection Industry Opportunities and Challenges
  4. 2.4 Dupilumab Injection Industry Restraints
3 Dupilumab Injection Market by Company
  1. 3.1 Global Dupilumab Injection Company Revenue Ranking in 2025
  2. 3.2 Global Dupilumab Injection Revenue by Company (2021-2026)
  3. 3.3 Global Dupilumab Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Dupilumab Injection Average Price by Company (2021-2026)
  5. 3.5 Global Dupilumab Injection Company Ranking (2024-2026)
  6. 3.6 Global Dupilumab Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Dupilumab Injection Company Product Type and Application
  8. 3.8 Global Dupilumab Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dupilumab Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dupilumab Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dupilumab Injection Market by Type
  1. 4.1 Dupilumab Injection Type Introduction
  2. 4.1.1 200mg (1.14mL)/Vial
  3. 4.1.2 300mg (2.0 mL)/Vial
  4. 4.2 Global Dupilumab Injection Sales Volume by Type
  5. 4.2.1 Global Dupilumab Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Dupilumab Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Dupilumab Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Dupilumab Injection Sales Value by Type
  9. 4.3.1 Global Dupilumab Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Dupilumab Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Dupilumab Injection Sales Value Share by Type (2021-2032)
5 Dupilumab Injection Market by Application
  1. 5.1 Dupilumab Injection Application Introduction
  2. 5.1.1 Asthma
  3. 5.1.2 Atopic Dermatitis
  4. 5.1.3 Chronic Sinusitis with Nasal Polyps
  5. 5.1.4 Other
  6. 5.2 Global Dupilumab Injection Sales Volume by Application
  7. 5.2.1 Global Dupilumab Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Dupilumab Injection Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Dupilumab Injection Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Dupilumab Injection Sales Value by Application
  11. 5.3.1 Global Dupilumab Injection Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Dupilumab Injection Sales Value by Application (2021-2032)
  13. 5.3.3 Global Dupilumab Injection Sales Value Share by Application (2021-2032)
6 Dupilumab Injection Regional Sales and Value Analysis
  1. 6.1 Global Dupilumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dupilumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Dupilumab Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Dupilumab Injection Sales by Region (2027-2032)
  5. 6.3 Global Dupilumab Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dupilumab Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dupilumab Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dupilumab Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Dupilumab Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dupilumab Injection Sales Value (2021-2032)
  12. 6.6.2 North America Dupilumab Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dupilumab Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Dupilumab Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dupilumab Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dupilumab Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dupilumab Injection Sales Value (2021-2032)
  21. 6.9.2 South America Dupilumab Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dupilumab Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dupilumab Injection Sales Value Share by Country, 2025 VS 2032
7 Dupilumab Injection Country-level Sales and Value Analysis
  1. 7.1 Global Dupilumab Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dupilumab Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dupilumab Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Dupilumab Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Dupilumab Injection Sales by Country (2027-2032)
  6. 7.4 Global Dupilumab Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dupilumab Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dupilumab Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dupilumab Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dupilumab Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dupilumab Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dupilumab Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dupilumab Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dupilumab Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dupilumab Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dupilumab Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dupilumab Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dupilumab Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dupilumab Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dupilumab Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dupilumab Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dupilumab Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dupilumab Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dupilumab Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dupilumab Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dupilumab Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dupilumab Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dupilumab Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dupilumab Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dupilumab Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dupilumab Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dupilumab Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dupilumab Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dupilumab Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dupilumab Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dupilumab Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dupilumab Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dupilumab Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Regeneron
  2. 8.1.1 Regeneron Company Information
  3. 8.1.2 Regeneron Business Overview
  4. 8.1.3 Regeneron Dupilumab Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Regeneron Dupilumab Injection Product Portfolio
  6. 8.1.5 Regeneron Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Dupilumab Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Dupilumab Injection Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dupilumab Injection Value Chain Analysis
  2. 9.1.1 Dupilumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dupilumab Injection Sales Mode & Process
  6. 9.2 Dupilumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dupilumab Injection Distributors
  9. 9.2.3 Dupilumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst